Abstract:

In developed countries, prostate cancer is the most frequently diagnosed cancer and the second most common cause of death from cancer in men. Because of t he widespread using of PSA test in screening program, most patients are diagnosed with low-risk clinically localized disease that can be treated effectively with surgery and radiotherapy. Nonetheless, about 15-20% of patients will be diagnosed with locally advanced or metastatic disease. Androgen deprivation therapy reduces tumor activity in about 80% of patients with advanced diseased, but most tumors relapse within 2 years to an incurable hormone-resistant state. Currently, every 3-week dosetaxel and daily prednisone is standard treatment option in hormone resistant prostate cancer (HRPC). The mean survival benefit in these therapy only measured 2 and 2.5 months. Median survival for HRPC patients treated with dosetaxel is now approximately 18-20 months. After progression on docetaxel, HRPC patients have a very poor prognosis, with median survival of approximately 6-10 months. Current treatment options for HRPC remain unsatisfactory and better management options are required. Understanding the signaling pathways involved in prostate carcinogenesis has lead to the development of a number of potential targeted new drugs such as antiangiogenic agents, specific inhibitors of key signalling molecules. This article reviews signaling pathways involved in prostate carcinogenesis and targeted therapy in HRPC.

Keywords: